Answers are grounded in this paper and cite their sources.
Treatment of MS with subcutaneous interferon-beta 1b (IFN-beta 1b) significantly reduces relapse rate and disease activity as demonstrated on serial MRI of the brain. [1-3] Although treatment is effective in many patients, initial side effects, like myalgia, chills, fever, and injection site reactions, which occur in more than one-third of patients, are still a major concern and may affect patient compliance.
No takes yet. Share an insight, caveat, or question.
Weber et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: